Michele M. Simkin is a distinguished partner at Foley & Lardner LLP, where she leverages her extensive expertise in intellectual property law to provide strategic business counseling to clients in the life sciences sector. As a member of the firm’s Management Committee since 2021, Michele...
Michele M. Simkin is a distinguished partner at Foley & Lardner LLP, where she leverages her extensive expertise in intellectual property law to provide strategic business counseling to clients in the life sciences sector. As a member of the firm’s Management Committee since 2021, Michele plays a pivotal role in shaping the firm’s strategic direction and enhancing its commitment to innovation and client service. Her leadership experience is underscored by her previous tenure as Chair of the Intellectual Property Department from 2015 to 2021, where she spearheaded initiatives that strengthened the firm’s position in patent litigation, patentability assessments, and technology transfer.
Michele’s deep understanding of the biotechnology landscape, coupled with her proficiency in patent prosecution and licensing, allows her to navigate complex legal challenges faced by her clients in the pharmaceutical industry. She has successfully managed high-stakes patent litigation cases, ensuring that her clients’ intellectual property rights are vigorously protected. Her role as Chair of the Biotechnology IP Practice Group from 2003 to 2009 further solidified her reputation as a thought leader in the field, where she focused on developing innovative strategies for patent protection and commercialization of cutting-edge biotechnological advancements.
With a career spanning over two decades at Foley & Lardner, Michele has cultivated a robust network of relationships within the life sciences community, enabling her to provide valuable insights that drive business growth and foster collaboration. Her commitment to excellence and her comprehensive understanding of the intricacies of intellectual property law make her a trusted advisor to clients navigating the ever-evolving landscape of biotechnology and pharmaceuticals.
